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Abstract: Axial gout is a well-documented but uncommon manifes-
tation of gout. Its mimicking nature and the impracticality of axial joint
aspiration might considerably delay its diagnosis. We report a case in a
normouricemic renal transplant recipient, whereby the primary symp-
tom of severe neck pain suggested pyogenic spondylodiscitis as an
initial tentative diagnosis. Clinical findings included a high C-reactive
protein concentration and elevated body temperature. The patient did
not respond to empiric antibiotic treatment and suffered consecutive
attacks of severe wrist and ankle pain in conjunction with a persistent
fever. Blood and joint cultures were negative, but analysis of aspirated
ankle joint fluid revealed monosodium urate crystals. A dual-energy
computed tomography scan confirmed the presence of monosodium
urate crystals in the costovertebral joints. Colchicine treatment
dramatically improved the patient’s clinical condition.
Axial gout should be considered in transplant recipients with severe
neck or back pain, fever, and increased inflammatory parameters with a
high likelihood of an infectious etiology, despite the presence of
paradoxically normal or even decreased serum urate concentrations.
Dual-energy computed tomography is a noninvasive technique of
possible benefit in the detection of axial gout when joint fluid aspiration
is not deemed safe.
(Medicine 94(13):e676)
Abbreviation: DECT = dual-energy computed tomography.
INTRODUCTION
G out is characterized by the deposition of monosodium uratecrystals in the synovial fluid of joints and soft tissue. It is
an increasingly common cause of inflammatory arthritis affect-
ing almost 2% of the population in industrialized countries andDer Meersch, MD MD, PhD,
ecke, MD, PhD
peripheral joints, but involvement of the axial spine has been
documented.4 The prevalence of axial gout is largely unknown,
but computed tomography (CT)-graphic evidence was observed
in 35% of the patients with a history of long-standing, poorly
controlled gout.5 Hyperuricemia is the main risk factor for
recurrent gout flares and is associated with a mature male
population in conjunction with diuretic and alcohol, especially
beer and spirits, intake.6 Serum uric acid concentrations above
6.8mg/dL might lead to supersaturation and formation of mono-
sodium urate crystals, with subsequent deposition into joints and
soft tissue causing gout attack.3,4 Transplant recipients are even
more at risk due to kidney dysfunction and exposure to cyclos-
porine, both ofwhich increase the serumuric acid concentration.3
Additionally, both cyclosporine and tacrolimus interact with
colchicine, increasing its half-life and thereby potentiating
toxicity.7,8
Clinical features of axial gout encompass a broad spectrum
ranging from radiculopathy, neurologic compression, or acute
back pain to a complete absence of symptoms. Its prevalence is
probably underestimated as this extensive array of symptoms
mimic other conditions such as spondylodiscitis, discogenic
disease, and osteoarthritis.4
The gold standard for diagnosing gout is the detection of
monosodium urate crystals in the joint fluid using polarized
light microscopy. Additionally, dual-energy CT (DECT) is a
highly specific and sensitive imaging modality, used increas-
ingly in the detection of crystal deposits in the joint.9
METHODS
Informed consent was obtained.
CASE REPORT
A 51-year-old white male laborer developed a febrile
syndrome of unknown origin, 2 months after renal transplan-
tation. He presented with a history of gouty arthritis and end-
stage kidney disease due to reflux nephropathy, for which he
received a second graft in June 2014; this was after the devel-
opment of end-stage kidney disease due to biopsy-proven
interstitial fibrosis and tubular atrophy in his first graft. He
was taking tacrolimus and mycophenolate mofetil as mainten-
ance immunosuppressive treatment after withdrawal of corti-
costeroids a few weeks before admission, following the
development of serous central chorioretinopathy. At presen-
tation, he complained of acute-onset severe dorsal pain, radiat-
ing to both shoulders. Both active and passive mobility of his
lower cervical spine were reduced and upon palpation was
tender. His body temperature was elevated (37.98C), but vitalination were unremarkable. Blood tests
-reactive protein (CRP) concentration
nge< 5.0mg/L) and a serum creatinine
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FIGURE 2. Serum uric acid during the course of the patient’s
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ular filtration rate of 54mL/min/1.73m2. White blood cell
count, liver function tests and serum uric acid concentration
were unremarkable. Neurological investigation and lumbar
puncture results were negative. Radiographic and CT-graphic
imaging of the cervical spine showed degenerative lesions. We
initiated intravenous analgetics and amoxicillin-clavulanic
acid, and his general condition improved slightly, with dimin-
ished pain and a decline in CRP.
Seven days after admission, he suddenly reexperienced
severe neck pain. Urgent magnetic resonance imaging (MRI) of
the spine disclosed degenerative lesions, consistent with the
earlier findings on CT- and radiographic imaging. No signs of
spondylodiscitis were visualized, and MRI offered no expla-
nation for his febrile syndrome; MRI of early vertebral osteo-
myelitis and discitis may, however, show nonspecific lesions.10
We subsequently conducted a positron emission tomography
(PET)-CT scan in order to find a focus of infection. The PET-
CT scan showed increased glucose metabolism at thoracic
vertebrae levels 1 and 2 (Figure 1). These findings on PET-
CT caused us to suspect spondylodiscitis, despite the negative
MRI imaging. We upgraded the antibiotic treatment to piper-
acillin/tazobactam and teicoplanin in response to spiking fever
with repeated negative blood, urine, and stool cultures. Never-
theless, he developed severe wrist and ankle pain over the
following days and remained febrile. During his hospital stay,
we did a thorough workup to uncover the focus of his assumed
infection. Repeated transthoracic and transesophageal ultraso-
nography of the heart did not reveal endocarditis. Culture and/or
polymerase chain reaction of bronchoalveolar lavage fluid
results were negative, including mycobacteria, fungi, and
yeasts, and we did not detect galactomannan antigen. Serologic
testing for brucella antibodies was negative. Bone marrow
puncture showed no abnormalities and Ziehl–Neelsen staining
was negative. We did not observe any location of increased
glucose metabolism on PET scans, other than the above-men-
tioned localization. Culture and Ziehl–Neelsen staining of the
joint fluid of both wrist and ankle were negative. However, we
did confirm the presence of monosodium urate crystals in
association with leukocytes (43000/mL and 95% polymorpho-
nuclear), on polarized light microscopy of the ankle joint
fluid. Serum uric acid was as low as 1.9mg/dL (normal range
3.4–7mg/dL) during the acute phase of his axial and peripheral
pain attacks (Figure 2).
Despite treatment with broad-spectrum antibiotics, the
Dhaese et alpatient remained febrile with a further CRP increase up to
276.7mg/L. This caused us to radically change our perspective.
We now considered axial gout as an explanation for the sudden-
FIGURE 1. PET/CT scan showing an increased glucose metab-
olism on the level of thoracic vertebrae 1 and 2. CT¼computed
tomography, PET¼positron emission tomography.
2 | www.md-journal.comonset axial pain and peripheral arthritis in this patient, as well as
his history of gout, the presence of monosodium urate crystals in
the ankle joint fluid, and recent interruption of corticosteroids.
Reminiscent of this, a DECT scan finally confirmed axial gout
(Figure 3) at the costovertebral joints of thoracic vertebrae 1 and
2, consistent with the location on PET/CT scan (Figure 1). Only
after we initiated colchicine at a dose of 1mg daily in 2 separate
doses did our patient completely recover; he was discharged in
good health with a normalized CRP. We started him on a
150mg daily dose of prophylactic allupurinol 2 weeks later.
Figure 4 depicts the patient’s clinical course and treatment
during the hospital stay. The serum CRP remained high despite
broad-spectrum antibiotic coverage. The course of the patient’s
clinical manifestations with the development of consecutive
attacks of severe neck, wrist, and ankle pain is outlined. Only
after initiation of colchicine, the CRP concentration reached the
normal range (<5mg/L) and the patient’s symptoms resolved.
DISCUSSION
In this case history, we initially suspected pyogenic spon-
dylodiscitis as the primary culprit. Despite a history of gout, the
index of suspicion for a gout attack was very low following the
initial localization, the findings on MRI, the spiking fever,
the low-to-normal uric acid, despite kidney dysfunction and
the use of tacrolimus instead of cyclosporine.
The incidental detection of monosodium urate crystals in
hospital stay with sudden decrease during the acute phase of the
arthritis episode and recovery after colchicine treatment.

, Start
colchicine treatment.the ankle joint fluid urged us to confirm the diagnosis of axial
gout on DECT as we did not consider spinal aspiration safe. The
gold standard in diagnosing gout, at least in atypical cases, is to
FIGURE 3. DECT images showing costovertebral deposition of
monosodium urate crystal deposition (in green) at the level of
thoracic vertebrae 1 and 2 (axial projection). DECT¼dual-energy
computed tomography.
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FIGURE 4. Timeline: CRP concentration in relation to clinical
manifestations and initiated treatment. , CRP (mg/L); 1, amox-
icillin-clavulanic acid (day 0); 2, upgrade to piperacillin-tazobac-
tam (day 10); 3, upgrade to piperacillin-tazobactamþ teicoplanin
(day 12); 4, upgrade to piperacillin-tazobactamþ teicoplaninþ
Medicine  Volume 94, Number 13, April 2015confirm monosodium urate crystals in the aspirated joint fluid.6
As this procedure is not always feasible, DECT might be of use.
In a recent diagnostic accuracy study, sensitivity of DECT in the
detection of monosodium urate crystals was 90%, and speci-
ficity was 83%.9
In this patient, the CT and MRI scans disclosed no
abnormalities other than degenerative lesions, and as such they
could not offer us an explanation for the patient’s febrile
syndrome. However, PET/CT scan showed an increased glu-
cose metabolism on the level of thoracic vertebrae 1 and 2,
consistent with the localization on DECT scan (Figures 1 and 3).
PET/CT scan is a highly sensitive technique to detect inflam-
mation, and this technique has recently been described as an
imaging technique in spinal and sacroiliac gout.11
During the acute phase of the gout attacks, our patient’s
serum uric acid dropped from within the normal range to
1.9mg/dL (normal range 3.4–7mg/dL) and normalized after
initiation of colchicine. Approximately 80% to 90% patients
with gout are hyperuricemic,12 but a normal serum uric acid
concentration at presentation does not exclude the disease.13
During the acute phase of the attack, serum concentrations of
uric acid are often decreased, possibly due to increased renal
urate excretion associated with the inflammatory reaction.6,14
The exact mechanism, however, remains elusive. It is possible
that antioxidant uric acid becomes increasingly consumed
through its scavenging of free radicals, produced in the inflam-
matory process.15
Both diagnosis and treatment in this patient were quite a
challenge. Corticosteroids were contraindicated considering his
ketoconazole (day 13); 5, Stop antibiotics, Start colchicine (day
24). CRP¼C-reactive protein.central chorioretinopathy, and nonsteroidal anti-inflammatory
drugswere avoided because of the potential risk of graft dysfunc-
tion. Nonsteroidal anti-inflammatory drugs can potentiate
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.calcineurin inhibitor toxicity.16 Although, by definition, nonster-
oidal anti-inflammatory drugs are not contraindicated in a renal
transplant patient with mild-to-moderate chronic kidney disease,
we were reluctant to prescribe them. We therefore considered
colchicine as the preferable treatment option.Hepatic CYP3A4 is
involved in the metabolism of colchine, which is a substrate for
P-glycoprotein, a transmembrane protein that excretes the drug
from the hepatocyte cannicular membrane into the bile. Tacro-
limus inhibits both the CYP3A4 enzyme and the P-glycoprotein,
potentiating the risk of toxic concentrations of colchicine.7 The
Food and Drug Administration suggests dose reduction or even
interruption of colchicine if treatment with a P-glycoprotein or
strong CYP3A4 inhibitor is required. Severe colchicine-induced
myopathy in tacrolimus-treated renal transplantations has been
reported.17 We failed, however, to detect any serum creatinine
kinase concentration increases during low-dose colchicine treat-
ment in our patient.
Interestingly, interleukin-1 inhibitors are an alternative
option in the control of an acute gout attack. Interleukin-1 is
a proinflammatory cytokine that plays a major role in the
inflammatory process during acute flares. To date, 3 interleu-
kin-1 inhibitors, anakinra, canakinumab, and rilonacept, are
currently under investigation for their use in the treatment of
gout. However, the efficacy of these interleukin-1 inhibitors has
yet to be further investigated. At present, the European Medi-
cines Agency has approved canakinumab for the treatment of
acute gout in adults who have undergone 3 or more attacks
within 12 months, in whom nonsteroidal anti-inflammatory
drugs and colchicine are either contraindicated or do not
provide an adequate response to first-line options, and in whom
repeated courses of corticosteroids are not appropriate.18 How-
ever, a recent Cochrane review highlighted the fact that there
are currently no trials comparing canakinumab to colchicine or
nonsteroidal anti-inflammatory drugs.19
Despite the patient’s normal serum uric acid concentrations,
we prescribed allopurinol as prophylaxis. Urate-lowering therapy
is indicated for patients with recurrent gout attacks, chronic
arthropathy, tophi, and gout with uric acid stones. The aim of
urate-lowering therapy is to maintain the urate concentration
below the saturation point of monosodium urate. Target serum
uric acid concentrations<6mg/dL are advised, but in severe gout
even lower concentrations are recommended as the rate of tophus
disappearance is inversely related to uricemia.1
We conclude that, despite the fact that gout typically
involves peripheral joints, axial gout should be considered in
every patient with severe axial pain, inflammation, and fever,
especially those with a history of gout. Diagnostic pitfalls are
its mimicking clinical nature, difficulties in joint aspiration,
and normal-to-low serum uric acid concentrations. Joint
aspiration and detection of monosodium urate crystals on
polarized light microscopy is superior to DECT in the diag-
nosis of gout in atypical cases; however, DECT might be
extremely helpful when joint puncture and fluid aspiration are
neither easy nor safe to perform.9 Colchicine toxicity should
be monitored in renal transplant recipients receiving cyclos-
porine or tacrolimus. Of key importance, early recognition of
the atypical nature of spinal gout might save time, money,
and, most importantly, greatly reduce a patient’s suffering
and pain.
Gouty Arthritis of the Spine: Case ReportACKNOWLEDGMENTS
We thank Sarah Knapp for her linguistic review of the
manuscript.
www.md-journal.com | 3
REFERENCES
1. Richette P, Bardin T. Gout. Lancet. 2010;375:318–328.
2. Clive DM. Renal transplant-associated hyperuricemia and gout.
JASN. 2000;11:974–979.
3. Abbott KC, Kimmel PL, Dharnidharka V, et al. New-onset gout
after kidney transplantation: incidence, risk factors and implications.
Transplantation. 2005;80:1383–1391.
4. Lumezanu E, Konatalapalli R, Weinstein A. Axial (spinal) gout.
Curr Rheumatol Rep. 2012;14:161–164.
5. Konatalapalli RM, Lumezanu E, Jelinek JS, et al. Correlates of axial
gout: a cross-sectional study. J Rheumatol. 2012;39:1445–1449.
6. Roddy E, Mallen CD, Doherty M. Gout. BMJ. 2013;347:f5648.
7. Amanova A, Kendi Celebi Z, Bakar F, et al. Colchicine levels in
chronic kidney diseases and kidney transplant recipients using
tacrolimus. Clin Transplant. 2014;28:1177–1183.
8. Garrouste C, Philipponnet C, Kaysi S, et al. Severe colchicine
intoxication in a renal transplant recipient on cyclosporine. Trans-
plant Proc. 2012;44:2851–2852.
9. Bongartz T, Glazebrook KN, Kavros SJ, et al. Dual-energy CT for
the diagnosis of gout: an accuracy and diagnostic yield study. Ann
Rheum Dis. 2014;Published Online First: 25/3/2014 doi:10.1136/
annrheumdis-2013-205095 [Epub ahead of print]:.
Dhaese et alearly vertebral osteomyelitis and discitis. Clin Radiol. 2010;65:974–
981.
4 | www.md-journal.com11. Cardoso FN, Omoumi P, Wieers G, et al. Spinal and sacroiliac gouty
arthritis: report of a case and review of the literature. Acta Radiol
Short Rep. 2014;3:2047981614549269.
12. Smith EU, Diaz-Torne C, Perez-Ruiz F, et al. Epidemiology of gout:
an update. Best Pract Res Clin Rheumatol. 2010;24:811–827.
13. Schlesinger N, Norquist JM, Watson DJ. Serum urate during acute
gout. J Rheumatol. 2009;36:1287–1289.
14. Urano W, Yamanaka H, Tsutani H, et al. The inflammatory process
in the mechanism of decreased serum uric acid concentrations during
acute gouty arthritis. J Rheumatol. 2002;29:1950–1953.
15. Waldron JL, Ashby HL, Razavi C, et al. The effect of the systemic
inflammatory response, as provoked by elective orthopaedic surgery,
on serum uric acid in patients without gout: a prospective study.
Rheumatology (Oxford). 2013;52:676–678.
16. Stamp LK, Chapman PT. Gout and organ transplantation. Curr
Rheumatol Rep. 2012;14:165–172.
17. Yousuf Bhat Z, Reddy S, Pillai U, et al. Colchicine-induced
myopathy in a tacrolimus-treated renal transplant recipient: case
report and literature review. Am J Ther. 2014doi:10.1097/
MJT.0000000000000044 [Epub ahead of print].
18. Schlesinger N. Anti-interleukin-1 therapy in the management of
Medicine  Volume 94, Number 13, April 2015gout. Curr Rheumatol Rep. 2014;16:398.
10. Dunbar JA, Sandoe JA, Rao AS, et al. The MRI appearances of19. Sivera F, Wechalekar MD, Andres M, et al. Interleukin-1 inhibitors
for acute gout. Cochrane database Syst Rev. 2014;9:CD009993.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
